🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT06667908
Recruiting Phase 2

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NCT06667908 · tracked via the Priya Life Science UK tracker
Sponsor
Johnson & Johnson Enterprise Innovation Inc.
Phase
Phase 2
Started
2024-12-06
Last updated
2026-08-28

Condition(s) studied

Carcinoma, Non-Small-Cell Lung

Investigational drug(s) / intervention(s)

JNJ-90301900DurvalumabConcurrent Chemo/Radiation Therapy (cCRT)Concurrent Chemo/Radiation Therapy (cCRT): CarboplatinConcurrent Chemo/Radiation Therapy (cCRT): Paclitaxel

JNJ-90301900: JNJ-90301900 will be injected intratumorally and/or intranodally.

Durvalumab: Durvalumab will be administered as intravenous (IV) infusion as cIT.

Concurrent Chemo/Radiation Therapy (cCRT): Radiation by intensity modulated radiation therapy (IMRT) will be administered.

Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin: Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy.

Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel: Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy.

Study summary

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Must be a candidate for standard of care (SOC) treatment of non small cell lung cancer (NSCLC) by concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation durvalumab treatment as determined by the investigator and per local guidelines at screening * Have a medical history of pathologically (histologically or cytologically) proven diagnosis of NSCLC within 3 months prior to enrollment/randomization * Have locally advanced unresectable stage III NSCLC according to the eighth edition lung cancer stage classification * Have at least 1 target lesion (primary lung lesion or involved lymph node\[s\]) per RECIST version 1.1 that is amenable to intratumoral and/or intranodal injection and intensity modulated radiation therapy (IMRT) as determined by the investigator at screening * Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1 Exclusion Criteria: * Medical history of: (a) Primary immunodeficiency (b) Organ transplant that requires therapeutic immunosuppression * Any of the following within 3 months prior to enrollment/randomization: severe or unstable angina, myocardial infarction, clinically significant ventricular arrhythmias or heart failure New York heart association functional classification class III to IV * Another concurrent or prior primary malignancy within the last 36 months at informed consent * Known allergies, hypersensitivity, or intolerance to any ingredients of JNJ-90301900 crystalline solution, platinum-based doublet chemotherapy (ChT), or durvalumab * History of coagulation disorders, including: (a) Active bleeding diathesis or requirement for therapeutic anticoagulation or antiplatelet that cannot be interrupted or altered for JNJ-90301900 injection procedures, (b) Major thromboembolic events (for example, pulmonary embolism, cerebrovascular accident) within 3 months of enrollment or randomization

Primary outcome measure(s)

Trial sites (43)

FacilityCityRegionStatus
Moores Cancer Center at UC San Diego Health La Jolla California Recruiting
University of Connecticut Health Center Farmington Connecticut Recruiting
Yale University New Haven Connecticut Recruiting
University of Miami Miami Florida Recruiting
Orlando Health Cancer Institute Orlando Florida Recruiting
Emory University Winship Cancer Institute Atlanta Georgia Recruiting
Beth Israel Deaconess Medical Center Boston Massachusetts Recruiting
Washington University in St Louis St Louis Missouri Recruiting
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey Recruiting
NYU Langone Health New York New York Recruiting
Memorial Sloan Kettering Cancer Center New York New York Recruiting
University of North Carolina at Chapel Hill Chapel Hill North Carolina Recruiting
FirstHealth of the Carolinas Pinehurst North Carolina Recruiting
University Hospitals Cleveland Medical Center Cleveland Ohio Recruiting
Oregon Health And Science University Portland Oregon Recruiting
University of Pennsylvania Philadelphia Pennsylvania Recruiting
MD Anderson Cancer Center Houston Texas Recruiting
University of Vermont Medical Center Burlington Vermont Recruiting
Royal Brisbane and Women's Hospital Herston Australia Recruiting
Sir Charles Gairdner Hospital Nedlands Australia Recruiting
Macquarie University North Ryde Australia Recruiting
Royal Melbourne Hospital Parkville Australia Recruiting
Fundacao Pio XII Barretos Brazil Recruiting
Sociedade Beneficente de Senhoras Hospital Sirio Libanes São Paulo Brazil Recruiting
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein São Paulo Brazil Recruiting
Dongguan People s Hospital Dongguan China Recruiting
The First Affiliated Hospital Sun Yat sen University Guangzhou China Recruiting
The Affiliated Cancer Hospital of Shandong First Medical University Jinan China Recruiting
Hopital De La Cavale Blanche Brest France Recruiting
Hopital Nord Marseille Marseille France Recruiting
Hopital Tenon Paris France Recruiting
Institut Curie Paris France Recruiting
Gustave Roussy Villejuif France Recruiting
Prince of Wales Hospital Shatin Hong Kong Recruiting
Antoni van Leeuwenhoek Amsterdam Netherlands Recruiting
Radboud Umcn Nijmegen Netherlands Recruiting
Hosp. Univ. 12 de Octubre Madrid Spain Recruiting
Clinica Univ. de Navarra Pamplona Spain Recruiting
Hosp. Clinico Univ. de Santiago Santiago de Compostela Spain Recruiting
Hosp. Univ. I Politecni La Fe Valencia Spain Recruiting

+ 3 more sites — see the full list on the official registry below.

On this site

📄 Imfinzi (durvalumab) drug profile →

More Johnson & Johnson Enterprise Innovation Inc. trials in the UK

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06667908 on ClinicalTrials.gov ↗ ← All trials in the UK